[
  {
    "ts": null,
    "headline": "Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold",
    "summary": "Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical indicators.",
    "url": "https://finnhub.io/api/news?id=d6e2bada4590e6cb2a8a0f476dcec9117273e7206fb178f2a5f2430389dceffb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736086947,
      "headline": "Amgen: Strong Fundamentals But Expensive Valuation Justifies A Hold",
      "id": 132279730,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical indicators.",
      "url": "https://finnhub.io/api/news?id=d6e2bada4590e6cb2a8a0f476dcec9117273e7206fb178f2a5f2430389dceffb"
    }
  }
]